News on trends and issues in the biopharm and pharmaceutical industry. Commentary on current events,clinical pipelines, facility expansions, competition, technology, legal and economic matters. M&A and licensing activity across the globe.
I am a Director of Research and Devopment for a leading supplier to biopharmaceutical producers. The views expressed are mine. I do not speak for any company or corporation.
In spirit of full disclosure and keeping potential readers abreast, I do not intend to start blogging in earnest until after the new year. I'll be travelling this week and will also be doing some level of research to get my first postings started. Expect next entries the week of Jan 4th.
I'm starting this as a discussion forum to espouse my views on what I perceive to be key trends in biotech. Particularly from my viewpoint as a raw material & services supplier to the industry. Equally, I'd like to hear from industry colleagues on their hot button issues. Quite frankly, I'd like direct feedback on my postings as to whether I'm on target or not with my perceptions of what are the important issues to work on and solve.
This is my first post - so I will not have much specific content to share today. However, I do plan to discuss a series of development (R&D) topics in my first series of posts dealing with raw material characterization of components used in cell culture, development of platform cell lines, media/feed sets, and processes as a comprehensive program, and high throughput & component streamlining approaches to medium development.
I encourage feedback as to whether these programs as described have merit, or how they might be modified to bring even greater value. Potentially, I think there is also the possibility of collaboration within the industry to speed learning & advances in these areas.